EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Infection Prophylaxis with Intravenous Immunoglobulin in Multiple Myeloma Patients Treated with Teclistamab

Michael Sheu, Sofia Molina Garcia, Meera Patel, Ali Mushtaq, Thomas Rust, Muhammad Anns Asif, Faiz Anwer, Aneela Majeed

Oncology · 2025

DOI: 10.1159/000548964 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2025. Verfasst von Michael Sheu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic, Internal Medicine, Cleveland, Ohio, USA, msheu3@gmail.com. Hauptthemen laut MEDLINE: Immunoglobulins, Intravenous, Multiple Myeloma, Antibodies, Bispecific. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

B-cell maturation antigen-targeting bispecific antibodies such as teclistamab have been associated with increased risk of infections as compared with conventional treatment regimens. This study explored the efficacy of intravenous immunoglobulin (IVIG) prophylaxis in reducing infection-related hospitalizations (IRHs) in MM patients who underwent treatment with teclistamab.

Methods

This was a retrospective study of MM treated with teclistamab at Taussig Cancer Center from December 16, 2022, to March 31, 2024. The primary endpoint was incidence rate of IRHs per patient-day on-IVIG vs. off-IVIG.

Results

Among the 44 patients included in the study, there were 19 infectious episodes that required inpatient hospitalization, occurring among 17 patients. Five infections occurred during 4,378 days during the “on-IVIG” period, compared to 14 infections occurring during 4,619 days for the “off-IVIG” period for an infectious incidence rate ratio between the two groups of 2.65 (p value = 0.027).

Conclusion

Patients treated with bispecific antibodies such as teclistamab are highly susceptible to infections due to impaired humoral immunity and hypogammaglobulinemia. Our findings demonstrate a reduction in infection incidence in patients while receiving IVIG. These results support the use of IVIG as an effective prophylactic strategy to reduce infectious risk in this vulnerable patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulins, IntravenousMultiple MyelomaAntibodies, BispecificHumansFemaleRetrospective StudiesMaleMiddle AgedAgedAdultAged, 80 and overIncidence

Stichwörter der Autor:innen

Bispecific antibodiesImmunoglobulinInfectionsMultiple myeloma

Substanzen

Immunoglobulins, IntravenousAntibodies, Bispecific

Autor:innen und Institutionen

  • Cleveland Clinic, Internal Medicine, Cleveland, Ohio, USA, msheu3@gmail.com.
  • Mayo Clinic. Infectious Disease, Rochester, New York, USA.
  • Cleveland Clinic, Internal Medicine, Cleveland, Ohio, USA.
  • Cleveland Clinic, Pharmacy, Cleveland, Ohio, USA.
  • Internal Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Cleveland Clinic, Hematology and Medical Oncology, Cleveland, Ohio, USA.

Zitieren

APA

Sheu, M., Molina Garcia, S., Patel, M., Mushtaq, A., Rust, T., Anns Asif, M., Anwer, F., & Majeed, A. (2025). Infection Prophylaxis with Intravenous Immunoglobulin in Multiple Myeloma Patients Treated with Teclistamab. Oncology. https://doi.org/10.1159/000548964

Vancouver

Sheu M, Molina Garcia S, Patel M, Mushtaq A, Rust T, Anns Asif M, et al. Infection Prophylaxis with Intravenous Immunoglobulin in Multiple Myeloma Patients Treated with Teclistamab. Oncology. 2025. doi:10.1159/000548964

BibTeX
@article{Sheu2025,
  author = {Sheu, Michael and Molina Garcia, Sofia and Patel, Meera and Mushtaq, Ali and Rust, Thomas and Anns Asif, Muhammad and Anwer, Faiz and Majeed, Aneela},
  title = {Infection Prophylaxis with Intravenous Immunoglobulin in Multiple Myeloma Patients Treated with Teclistamab},
  journal = {Oncology},
  year = {2025},
  doi = {10.1159/000548964}
}
Kostenlos starten →